Promoting clinical benefits of an interchangeable over standard biosimilars is likely to be considered false and misleading by the FDA. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
